17 August 2018 - The recommendations from the July 2018 PBAC meeting are now available.

Submissions

• 66 submissions were considered by the PBAC; 63 relate to the listing of a medicine or medicinal preparation on the Pharmaceutical Benefits Scheme; the remaining three relate to the listing of a vaccine on the National Immunisation Program
  
• All 66 submissions were lodged by a sponsor/pharmaceutical company (i.e. there were no third-party submissions)
  
• 35 (53%) were major submissions
  
• 45 (68%) were initial submissions and 21 (32%) were resubmissions
  
• 13 (20%) submissions were for a ‘new medicine’
  
• 17 26%) submissions included a CEA/CUA. The type of economic evaluation in some submissions is as yet unknown.
  
• 30 (45%) submissions were for medicines in WHO ATC Group L (anti-neoplastic and immunomodulating agents), 7 (11%) were for medicines in WHO ATC Group A (alimentary tract and metabolism) and 7 (11%) were for medicines in WHO ATC Group J (anti-infectives)
  
• Two submissions appear to have been withdrawn
  
• The PBAC considered a few minor submissions that were not included in the published agenda
  

Outcomes

• The 66 submissions yielded 99 outcomes; 80 (81%) recommendations, 16 (12%) rejections, 2 (2%) deferrals and 1 (1%) no outcome. Insofar as some submissions included multiple requests; the number of outcomes exceeds the number of submissions.
  
• Six of the 13 submissions for a new medicine considered by the PBAC were recommended
  
• The 17 submissions that are known to have included a CEA/CUA yielded 20 outcomes; 9 (53%) recommendations and 7 (41%) rejections
  
• Eight of the 16 rejections were for medicines in WHO ATC Group L (some of these rejections are for a medicine that is not used by patients with cancer)
  
• The 21 resubmissions yielded 21 outcomes of which 17 (81%) were recommendations
  

Read PBAC outcomes